

**899 NORTH CAPITOL STREET, NE
2ND FLOOR
WASHINGTON, DC 20002**

October 5, 2023

Time: 9:30 am

**OPEN SESSION AGENDA
(IN-PERSON AND WEBEX)**

Board of Pharmacy Mission Statement:

"To protect and improve the public health through the efficient and effective regulation of the practice of Pharmacy and Pharmaceutical Detailing; through the licensure of Pharmacists, Pharmaceutical Detailers, Pharmacy Interns, and Pharmacy Technicians."

CALL TO ORDER:

PRESIDING:

BOARD MEMBERSHIP/ATTENDANCE:

BOARD MEMBERS:		
	DR. TAMARA McCANTS, PHARM.D. R.PH CHAIRPERSON	
	MR. ALAN FRIEDMAN, R.PH, VICE CHAIRPERSON	
	DR. BENJAMIN MILES, PHARM.D. R.PH	
	DR. ASHLEE BOW, PHARM.D. R.PH	
	DR. ALLISON HILL, PHARM.D. R.PH	
STAFF:	DR. JUSTIN ORTIQUE, EXECUTIVE DIRECTOR	
	KARIN BARRON, HEALTH LICENSING SPECIALIST	
	LUANNE GREENAWAY, PROGRAM SPECIALIST	
	COUNTEE GILLIAM, BOARD INVESTIGATOR	
LEGAL STAFF:	CARLA WILLIAMS, SENIOR ASSISTANT GENERAL COUNSEL	
VISITORS:		

Open Session Agenda

Quorum:

Introduction:		
1005-O-01	<u>Approval of the Open Session Meeting Minutes for:</u> August 3, 2023 September 7, 2023	
<u>Consent Agenda</u>	None	
<u>Chairperson Report</u>	<u>Interprofessional Workgroup</u>	Dr. Tamara McCants
<u>Executive Director Report</u>	<ul style="list-style-type: none">▪ Statistical Report on Pharmacy Professionals in the District of Columbia▪ Prescription Drug Monitoring Program Updates▪ DCRx (DC Center for Rational Prescribing)▪ Board of Pharmacy Vacancies: https://motaboardstheresumator.com/apply/1L8k6Q/Board-Of-Pharmacy	Dr. Justin Ortique
<u>Office of Government Relations (OGR) Report</u>	<u>DC Health Director Confirmation Hearing</u> <ul style="list-style-type: none">▪ On October 5th at 10 AM, the Committee on Health will hold a hearing on the Director of the Department of Health Dr. Ayanna Bennett Confirmation Resolution of 2023 (PR25-0290). <u>Council Recess</u> <ul style="list-style-type: none">▪ Council has reconvened from recess, and we anticipate a busy fall.	
<u>Senior Assistant General Counsel Report</u>		
1005-O-02	<u>Notice of Emergency and Proposed Rulemaking to Allow Pharmacists to Administer RSV Vaccinations</u> (a) Amendments to Title 17 DCMR For Pharmacist Chapter 65 section 6512.7 (Administration of Immunizations and Vaccinations by Pharmacists)	Ms. Carla Williams

<u>Subcommittee Reports</u>		
1005-O-03	<u>Legislative and Regulatory Subcommittee Report</u>	Mr. Alan Friedman
1005-O-04	<u>Communications Subcommittee Report</u>	Dr. Ashlee Bow
<u>Presentation</u>		
1005-O-05	Respiratory Season Plans	Ms. Heather Burris
<u>Matter for Consideration</u>		
1005-O-06	National Association of Boards of Pharmacy (NABP) New Pharmacist Exam Eligibility Service	
NABP E-Newsletter	<p>September 20, 2023</p> <p>FDA Advisory Panel Determines Oral Phenylephrine Ineffective in OTC Medications</p> <p>FDA Authorizes Emergency Use of Updated COVID-19 Vaccines for 2023-2024</p> <p>HHS Proposes Rule to Prohibit Discrimination Based on Disability in Health Care and Human Service Programs</p> <p>LAPPA Publishes Report on Status of Good Samaritan Fatal Overdose Prevention Laws in US</p> <p>UMass Memorial Medical Center’s Mobile Addiction Service Helped Over 1,100 Individuals Within a Two-Year Period</p> <p>September 27, 2023</p> <p>APhA, ASHP, and NABP Unveil Strategies to Bolster Pharmacy Workforce</p> <p>FDA Issues Document on Regulation of Prescription Drug Use-Related Software</p> <p>Nearly \$300 Million Awarded to 49 States, District of Columbia, and 40 Local Health Departments for Drug Overdose Prevention</p> <p>Innovations: Ten Years After DSCSA, Final Provisions Set to Go Into Effect</p> <p>In 2021, 72% of Adults Who Acknowledged Having a Substance Use Problem Reported Being in Recovery or Recovering From Substance Use</p>	Dr. Tamara McCants

	<p>States With Less Restrictive Telepharmacy Policies Experienced Fewer Pharmacy Deserts, According to Recent Study</p> <p>About One in Five Adults With OUD Receive Medication Treatment, Based on the 2021 NSDUH</p> <p>Note to the Public: To receive weekly updates from NABP, please sign up by using the following link: https://nabp.pharmacy/newsroom/news/.</p>	
<u>Comments from the Public</u>		
<u>Motion to Adjourn the Open Session</u>	<p>"Madam Board Chair, I move that the Board close the Open Public session portion of the meeting and move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the following purposes: to discuss disciplinary matters pursuant to § 2-575(b)(9); to seek the advice of counsel to the board, to preserve the attorney-client privilege, or to approve settlement agreements pursuant to § 2-575(b)(4); and to plan, discuss, or hear reports concerning ongoing or planned investigations pursuant to § 2-575(b)(14)." ROLL CALL VOTE</p>	

This concludes the Public Open Session of the meeting. The Board will now move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the reasons set forth in the motion.

Open Session Meeting Adjourned at :

This meeting is governed by the Open Meetings Act. Please address any questions or complaints arising under this meeting to the Office of Open Government at opengovoffice@dc.gov.